A double-blind comparative study of BFE 1224 for patients with tinea unguiuma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Jan 2018 New trial record
19 Jan 2018 According to an Eisai Co Ltd media release, NAILIN Capsules 100mg containing the active ingredient fosravuconazole L-lysine ethanolate (fosravuconazole) has recieved marketing and manufacturing for the treatment of onychomycosis in Japan on January 19, 2018.
19 Jan 2018 According to an Eisai Co Ltd media release, after confirming efficacy and safety in the study, Sato Pharma applied for marketing and manufacturing authorization in January 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com